Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug;20(4):251-260.
doi: 10.1007/s11904-023-00662-0. Epub 2023 Jun 21.

Update on the Impact of Depot Medroxyprogesterone Acetate on Vaginal Mucosal Endpoints and Relevance to Sexually Transmitted Infections

Affiliations
Review

Update on the Impact of Depot Medroxyprogesterone Acetate on Vaginal Mucosal Endpoints and Relevance to Sexually Transmitted Infections

Smritee Dabee et al. Curr HIV/AIDS Rep. 2023 Aug.

Abstract

Purpose of review: The long-acting reversible intramuscularly-injected contraceptive depot medroxyprogesterone acetate (DMPA-IM) is widely used by cisgender women in Africa. Although DMPA-IM provides reliable contraception, potential effects on the female genital tract (FGT) mucosa have raised concern, including risk of HIV infection. This review summarises and compares evidence from observational cohort studies and the randomised Evidence for Contraceptive Options in HIV Outcomes (ECHO) Trial.

Recent findings: Although previous observational studies found women using DMPA-IM had higher abundance of bacterial vaginosis (BV)-associated bacteria, increased inflammation, increased cervicovaginal HIV target cell density, and epithelial barrier damage, sub-studies of the ECHO Trial found no adverse changes in vaginal microbiome, inflammation, proteome, transcriptome, and risk of viral and bacterial STIs, other than an increase in Th17-like cells. Randomised data suggest that DMPA-IM use does not adversely change mucosal endpoints associated with acquisition of infections. These findings support the safe use of DMPA-IM in women at high risk of acquiring STIs, including HIV.

Keywords: Depot medroxyprogesterone acetate; ECHO Trial; Epithelial barrier; Immune cells; Inflammation; Vaginal microbiome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Alkema L, Kantorova V, Menozzi C, Biddlecom A. National, regional, and global rates and trends in contraceptive prevalence and unmet need for family planning between 1990 and 2015: a systematic and comprehensive analysis. Lancet [Internet]. 2013;381:1642–52. Available from: https://www.sciencedirect.com/science/article/pii/S0140673612622041. Accessed 28 Nov 2022 - PubMed
    1. Tsui AO, Brown W, Li Q. Contraceptive practice in sub-Saharan Africa. Popul Dev Rev [Internet]. 2017;43:166–91. Available from: 10.1111/padr.12051. - PMC - PubMed
    1. Smith JA, Heffron R, Butler AR, Celum C, Baeten JM, Hallett TB. Could misreporting of condom use explain the observed association between injectable hormonal contraceptives and HIV acquisition risk? Contraception. 2017;95:424–430. doi: 10.1016/j.contraception.2016.12.003. - DOI - PMC - PubMed
    1. Baeten JM, Heffron R. Contraception and sexually transmitted infections: risks and benefits, hypotheses and evidence. Lancet Glob Health. 2015;3:e430–e431. doi: 10.1016/S2214-109X(15)00085-6. - DOI - PubMed
    1. Polis CB, Curtis KM, Hannaford PC, Phillips SJ, Chipato T, Kiarie JN, Westreich DJ, Steyn PS. An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women. AIDS. 2016;30(17):2665–83. 10.1097/QAD.0000000000001228. - PMC - PubMed

Publication types

Substances